Which statement accurately reflects thalidomide's use in SJS/TEN?

• A. Increases mortality
• B. DO NOT USE for SJS/TEN (CI)
• C. Provides a cure
• D. Is recommended for all patients

Answer: (B)

Thalidomide has no proven role in treating SJS/TEN and is considered contraindicated. In these conditions, the focus is on stopping the offending drug and providing intensive supportive care (burn-unit–level wound management, fluid and electrolyte balance, infection prevention, and pain control). There’s no solid evidence that thalidomide improves outcomes in SJS/TEN, and it carries significant risks—its teratogenic potential, plus other adverse effects like neuropathy, thromboembolism, and systemic toxicity—make its use inappropriate. So, the statement that it should not be used for SJS/TEN accurately reflects current practice. The other options imply benefits or universal use that aren’t supported by evidence or guidelines.